Efficacy and auditory biomarker analysis of fronto-temporal transcranial direct current stimulation (tDCS) in targeting cognitive impairment associated with recent-onset schizophrenia: study protocol for a multicenter randomized double-blind sham-controlled trial

• Published in: Current controlled trials in cardiovascular medicine 2023-02, Vol.24 (1), p.141-141, Article 141
• Main Authors: Dondé, Clément, Bastin, Julien, Pouchon, Arnaud, Costes, Nicolas, Fakra, Eric, Galvão, Filipe, Gay, Aurélia, Haesebaert, Frédéric, Lamalle, Laurent, Mérida, Inès, Rigon, Maxence, Schneider, Fabien, Troprès, Irène, Brunelin, Jérôme, Polosan, Mircea
• Format: Article
• Language: English
• Subjects: Analysis; Biological markers; Biomarkers; Brain stimulation; Care and treatment; Cognition & reasoning; Cognitive ability; Cognitive impairment; Cognitive science; Diagnosis; Double-blind studies; Hallucinations; Human health and pathology; Life expectancy; Life Sciences; Memory; Methods; Neuroscience; Neurosciences; Noninvasive brain stimulation; Psychiatrics and mental health; Psychiatry; RCT; Research centers; Schizophrenia; Study Protocol; tDCS; Young adults
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-023-07160-z

In parallel to the traditional symptomatology, deficits in cognition (memory, attention, reasoning, social functioning) contribute significantly to disability and suffering in individuals with schizophrenia. Cognitive deficits have been closely linked to alterations in early auditory processes (EAP) that occur in auditory cortical areas. Preliminary evidence indicates that cognitive deficits in schizophrenia can be improved with a reliable and safe non-invasive brain stimulation technique called tDCS (transcranial direct current stimulation). However, a significant proportion of patients derive no cognitive benefits after tDCS treatment. Furthermore, the neurobiological mechanisms of cognitive changes after tDCS have been poorly explored in trials and are thus still unclear. The study is designed as a randomized, double-blind, 2-arm parallel-group, sham-controlled, multicenter trial. Sixty participants with recent-onset schizophrenia and cognitive impairment will be randomly allocated to receive either active (n=30) or sham (n=30) tDCS (20-min, 2-mA, 10 sessions during 5 consecutive weekdays). The anode will be placed over the left dorsolateral prefrontal cortex and the cathode over the left auditory cortex. Cognition, tolerance, symptoms, general outcome and EAP (measured with EEG and multimodal MRI) will be assessed prior to tDCS (baseline), after the 10 sessions, and at 1- and 3-month follow-up. The primary outcome will be the number of responders, defined as participants demonstrating a cognitive improvement ≥Z=0.5 from baseline on the MATRICS Consensus Cognitive Battery total score at 1-month follow-up. Additionally, we will measure how differences in EAP modulate individual cognitive benefits from active tDCS and whether there are changes in EAP measures in responders after active tDCS. Besides proposing a new fronto-temporal tDCS protocol by targeting the auditory cortical areas, we aim to conduct a randomized controlled trial (RCT) with follow-up assessments up to 3 months. In addition, this study will allow identifying and assessing the value of a wide range of neurobiological EAP measures for predicting and explaining cognitive deficit improvement after tDCS. The results of this trial will constitute a step toward the use of tDCS as a therapeutic tool for the treatment of cognitive impairment in recent-onset schizophrenia. ClinicalTrials.gov NCT05440955. Prospectively registered on July 1 , 2022.